Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Cancer., May;106(10):2208-17 (2006)
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
Journal of Thoracic Oncology
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
Annals of Oncology
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Clinical Cancer Research
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Lung cancer incidence in never smokers.
Journal of Clinical Oncology